|Day Low/High||4.75 / 4.92|
|52 Wk Low/High||2.85 / 7.21|
Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.
Flexion Therapeutics and BioDelivery Sciences International have promising products that should do well once the fixation on Covid-19 treatments wanes.
DropBox and BioDelivery Sciences are names to consider during the market choppiness of the coming weeks.
Here's my strategy which has worked particularly well.
The trio of BioDelivery Sciences, Omeros and TG Therapeutics looks well-positioned to capitalize on their potential in the New Year.
BioDelivery Sciences International, Chiasma Inc. and TherapeticsMD all feature promising treatments.
The trio consists of BioDelivery Sciences International, Beazer Homes USA and Redhill Biopharma.
Both Digital Turbine and BioDelivery Sciences have done well in 2019.
I am incrementally using buy-write option orders to add some shares to core holdings.
Here are updates on small biotech/biopharma names I have profiled before.
Let's look at a couple of companies we have covered on these pages before.
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
Portola Pharmaceuticals, Flexion Therapeutics and BioDelivery Sciences delivered nice third-quarter numbers.
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
We are coming my favorite part of earnings season -- when these small-caps report.
We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.
Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
We answer recent reader questions about three of the biotech stocks we regularly cover.
Not much action in the markets since our last update with the major indices continuing to grind slightly higher as we try to close out a solid first trading week of 2017 on a high note. Think Teva Pharmaceuticals getting oversold today on slightly r...
This biopharma company's Relistor drug should send revenues sharply higher this year.